ETNB
Price
$14.71
Change
-$0.03 (-0.20%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
2.19B
43 days until earnings call
SLS
Price
$1.63
Change
-$0.08 (-4.71%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
212.47M
49 days until earnings call
Interact to see
Advertisement

ETNB vs SLS

Header iconETNB vs SLS Comparison
Open Charts ETNB vs SLSBanner chart's image
89bio
Price$14.71
Change-$0.03 (-0.20%)
Volume$37.94K
Capitalization2.19B
SELLAS Life Sciences Group
Price$1.63
Change-$0.08 (-4.71%)
Volume$32.41K
Capitalization212.47M
ETNB vs SLS Comparison Chart in %
Loading...
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ETNB vs. SLS commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ETNB is a Hold and SLS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (ETNB: $14.74 vs. SLS: $1.70)
Brand notoriety: ETNB and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ETNB: 300% vs. SLS: 84%
Market capitalization -- ETNB: $2.19B vs. SLS: $212.47M
ETNB [@Biotechnology] is valued at $2.19B. SLS’s [@Biotechnology] market capitalization is $212.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ETNB’s FA Score shows that 0 FA rating(s) are green whileSLS’s FA Score has 0 green FA rating(s).

  • ETNB’s FA Score: 0 green, 5 red.
  • SLS’s FA Score: 0 green, 5 red.
According to our system of comparison, ETNB is a better buy in the long-term than SLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ETNB’s TA Score shows that 5 TA indicator(s) are bullish while SLS’s TA Score has 3 bullish TA indicator(s).

  • ETNB’s TA Score: 5 bullish, 5 bearish.
  • SLS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ETNB is a better buy in the short-term than SLS.

Price Growth

ETNB (@Biotechnology) experienced а +84.94% price change this week, while SLS (@Biotechnology) price change was +1.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

ETNB is expected to report earnings on Nov 06, 2025.

SLS is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ETNB($2.19B) has a higher market cap than SLS($212M). ETNB YTD gains are higher at: 88.491 vs. SLS (63.462). SLS has higher annual earnings (EBITDA): -27.18M vs. ETNB (-442.86M). ETNB has more cash in the bank: 561M vs. SLS (25.3M). SLS has less debt than ETNB: SLS (737K) vs ETNB (37.6M). ETNB (0) and SLS (0) have equivalent revenues.
ETNBSLSETNB / SLS
Capitalization2.19B212M1,033%
EBITDA-442.86M-27.18M1,629%
Gain YTD88.49163.462139%
P/E RatioN/AN/A-
Revenue00-
Total Cash561M25.3M2,217%
Total Debt37.6M737K5,102%
FUNDAMENTALS RATINGS
ETNB vs SLS: Fundamental Ratings
ETNB
SLS
OUTLOOK RATING
1..100
8474
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3649
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ETNB's Valuation (39) in the null industry is in the same range as SLS (56) in the Biotechnology industry. This means that ETNB’s stock grew similarly to SLS’s over the last 12 months.

ETNB's Profit vs Risk Rating (100) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to SLS’s over the last 12 months.

ETNB's SMR Rating (99) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to SLS’s over the last 12 months.

ETNB's Price Growth Rating (36) in the null industry is in the same range as SLS (49) in the Biotechnology industry. This means that ETNB’s stock grew similarly to SLS’s over the last 12 months.

ETNB's P/E Growth Rating (100) in the null industry is in the same range as SLS (100) in the Biotechnology industry. This means that ETNB’s stock grew similarly to SLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ETNBSLS
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 7 days ago
85%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 9 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ETNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SREYX16.420.12
+0.74%
SEI Real Estate Y (SIMT)
FANAX47.47N/A
N/A
Fidelity Advisor Energy A
MSDVX21.01N/A
N/A
BlackRock Equity Dividend Svc
ARTLX15.67-0.01
-0.06%
Artisan Value Investor
UIAGX80.13-0.97
-1.20%
Victory Aggressive Growth Institutional

SLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLS has been loosely correlated with AKRO. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SLS jumps, then AKRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLS
1D Price
Change %
SLS100%
-1.16%
AKRO - SLS
43%
Loosely correlated
+3.08%
ARGNF - SLS
36%
Loosely correlated
N/A
SABS - SLS
27%
Poorly correlated
-8.87%
TECX - SLS
25%
Poorly correlated
-4.25%
ETNB - SLS
25%
Poorly correlated
-0.87%
More